Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.3
2.4
Journals
Veterinary Sciences
Special Issues
Epigenetic Factors of Embryological Development and Tumorigenesis
share announcement

Epigenetic Factors of Embryological Development and Tumorigenesis

A special issue of Veterinary Sciences (ISSN 2306-7381).

Deadline for manuscript submissions: closed (15 March 2021) | Viewed by 11392

Special Issue Editor

Dr. Mark A. Brown

E-Mail Website
Guest Editor
College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1005 Campus Delivery, Fort Collins, CO 80523, USA
Interests: targeted therapy; oncology; small molecular inhibitors; monoclonal antibodies; gene targeting; protein targeting
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colelagues,

The development of organisms involves the regulation of patterns in gene expression. Those patterns are often set in a heritable condition through epigenetic modifications and associated pathways of cellular memory. In this way, the widespread synchronization in genetic patterns of expression ultimately determines cellular differentiation and developmental consequences during embryogenesis. Epigenetic aberrations are known to be associated with a range of developmental diseases and, in mature tissues, can also be associated with tumorigenic events. For this special issue, we invite papers related to the molecular, cellular, and developmental significance of epigenetics during embryological development as well as developmental and oncological diseases associated with epigenetic aberrations.

Dr. Mark Brown
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Veterinary Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenetics
  • embryogenesis
  • developmental biology
  • epigenetic aberrations

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

7 pages, 971 KiB  
Article
The Lysine Methyltransferase SMYD2 Is Required for Definite Hematopoietic Stem Cell Production in the Mouse Embryo
by Melissa A. Edwards, Mark A. Brown, Ilham Alshiraihi, Dillon K. Jarrell and Haley O. Tucker
Vet. Sci. 2020, 7(3), 100; https://doi.org/10.3390/vetsci7030100 - 25 Jul 2020
Cited by 2 | Viewed by 3120
Abstract
The five-membered SET and MYND domain-containing lysine methyltransferase (SMYD) family plays pivotal roles in development and differentiation. Initially characterized within the cardiovascular system, one such member, SMYD2, has been implicated in transcriptional and apoptotic regulation of hematopoiesis. Deletion of Smyd2 in adult mouse [...] Read more.
The five-membered SET and MYND domain-containing lysine methyltransferase (SMYD) family plays pivotal roles in development and differentiation. Initially characterized within the cardiovascular system, one such member, SMYD2, has been implicated in transcriptional and apoptotic regulation of hematopoiesis. Deletion of Smyd2 in adult mouse Hemaopoietic Stem Cells (HSC) using an interferon-inducible mx1-Cre-mediated conditional knockout (CKO) led to HSC reduction via both apoptosis and transcriptional deficiencies. Since HSC are specified from hemogenic endothelial (HE) cells in the dorsal aorta (DA), we sought to determine whether the flaw in HSC originated embryologically from this site. Toward this end, we performed deletion with vav-Cre mice, which is active in all hematopoietic and endothelial tissues from E10.5 embryonic life onward. Unexpectedly, we observed no defects in the embryo, other than apoptotic loss of definite HSC, whereas adult hematopoietic populations downstream were unaffected. These results further establish the importance of SMYD2 in antiapoptotic gene control of gene expression from the embryo to the adult. Full article
(This article belongs to the Special Issue Epigenetic Factors of Embryological Development and Tumorigenesis)
►▼ Show Figures

Graphical abstract

9 pages, 1865 KiB  
Communication
Characterizing the Role of SMYD2 in Mammalian Embryogenesis—Future Directions
by Dillon K. Jarrell, Kelly N. Hassell, Debbie C. Crans, Shari Lanning and Mark A. Brown
Vet. Sci. 2020, 7(2), 63; https://doi.org/10.3390/vetsci7020063 - 12 May 2020
Cited by 5 | Viewed by 3751
Abstract
The SET and MYND domain-containing (SMYD) family of lysine methyltransferases are essential in several mammalian developmental pathways. Although predominantly expressed in the heart, the role of SMYD2 in heart development has yet to be fully elucidated and has even been shown to be [...] Read more.
The SET and MYND domain-containing (SMYD) family of lysine methyltransferases are essential in several mammalian developmental pathways. Although predominantly expressed in the heart, the role of SMYD2 in heart development has yet to be fully elucidated and has even been shown to be dispensable in a murine Nkx2-5-associated conditional knockout. Additionally, SMYD2 was recently shown to be necessary not only for lymphocyte development but also for the viability of hematopoietic leukemias. Based on the broad expression pattern of SMYD2 in mammalian tissues, it is likely that it plays pivotal roles in a host of additional normal and pathological processes. In this brief review, we consider what is currently known about the normal and pathogenic functions of SMYD2 and propose specific future directions for characterizing its role in embryogenesis. Full article
(This article belongs to the Special Issue Epigenetic Factors of Embryological Development and Tumorigenesis)
►▼ Show Figures

Figure 1

15 pages, 2185 KiB  
Article
Nitric Oxide as a Potential Adjuvant Therapeutic for Neuroblastoma: Effects of NO on Murine N2a Cells
by Jenna L. Gordon, Melissa M. Reynolds and Mark A. Brown
Vet. Sci. 2020, 7(2), 51; https://doi.org/10.3390/vetsci7020051 - 23 Apr 2020
Cited by 5 | Viewed by 3983
Abstract
Neuroblastoma, the most common extracranial solid tumor in children, accounts for 15% of all pediatric cancer deaths. Pharmaceutical applications of S-Nitrosylation, which, under normal conditions is involved with a host of epigenetic and embryological development pathways, have exhibited great potential for use as [...] Read more.
Neuroblastoma, the most common extracranial solid tumor in children, accounts for 15% of all pediatric cancer deaths. Pharmaceutical applications of S-Nitrosylation, which, under normal conditions is involved with a host of epigenetic and embryological development pathways, have exhibited great potential for use as adjuvant therapeutics in the clinical management of cancer. Herein, an evaluation of the impact of nitric oxide (NO) as a potent anticancer agent on murine neuroblastoma cells is presented. Excitingly cell viability, colony formation, and non-carcinogenic cell analysis illustrate the significance and practicality of NO as a cytotoxic anticancer therapeutic. Resazurin, WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt), and MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphyltetrazolium bromide) assays consistently displayed a moderate, ~20–25% reduction in cell viability after exposure to 1 mM S-Nitrosoglutathione (GSNO). A colony formation assay demonstrated that treated cells no longer exhibited colony formation capacity. Identically GSNO-treated Adult Human Dermal Fibroblasts (HDFa) exhibited no decrease in viability, indicating potential discrimination between neoplastic and normal cells. Collectively, our findings indicate a potential application for NO as an adjuvant therapeutic in the clinical management of neuroblastoma. Full article
(This article belongs to the Special Issue Epigenetic Factors of Embryological Development and Tumorigenesis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop